

HEPARIN SODIUM IN DEXTROSE- heparin sodium and dextrose injection

B. Braun Medical Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use HEPARIN SODIUM IN 5% DEXTROSE INJECTION safely and effectively. See full prescribing information for HEPARIN SODIUM IN 5% DEXTROSE INJECTION.

HEPARIN SODIUM IN 5% DEXTROSE INJECTION, for intravenous use
Initial U.S. Approval: 1939

INDICATIONS AND USAGE

Heparin sodium is indicated for: (1)

- Prophylaxis and treatment of venous thrombosis and pulmonary embolism;
- Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation;
- Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation);
- Prevention of clotting in arterial and cardiac surgery;
- Prophylaxis and treatment of peripheral arterial embolism;
- Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

DOSAGE AND ADMINISTRATION

Recommended Adult Dosages:

- Therapeutic Anticoagulant Effect with Full-Dose Heparin* (2.3)

Intermittent Intravenous Injection	Initial Dose	10,000 Units
	Subsequent Doses	5,000 to 10,000 Units every 4 to 6 hours
Continuous Intravenous Infusion	Initial Dose	5,000 Units by intravenous injection
	Continuous	20,000 to 40,000 Units every 24 hours

* Based on 150 lb. (68 kg) patient.

- Cardiovascular Surgery (2.5)

Intravascular via Total Body Perfusion	Initial Dose	Greater than or equal to 150 units/kg; adjust for longer procedures
--	--------------	---

- Extracorporeal Dialysis (2.8)

Intravascular via Extracorporeal Dialysis	Follow equipment manufacturer's operating directions carefully.
---	---

For pediatric dosing see section 2.4 of full prescribing information.

DOSAGE FORMS AND STRENGTHS

- Heparin Sodium 20,000 USP units per 500 mL (40 USP units per mL) in 5% Dextrose Injection (3)
- Heparin Sodium 25,000 USP units per 500 mL (50 USP units per mL) in 5% Dextrose Injection (3)
- Heparin Sodium 25,000 USP units per 250 mL (100 USP units per mL) in 5% Dextrose Injection (3)

CONTRAINDICATIONS

- History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT) (5.3)
- Known hypersensitivity to heparin or pork products (5.7)
- In whom suitable blood coagulation tests cannot be performed at appropriate intervals (5.5)
- Uncontrollable active bleeding state, except when this is due to disseminated intravascular coagulation (5.2)

WARNINGS AND PRECAUTIONS

- Fatal Medication Errors: Confirm choice of correct strength prior to administration. (5.1)
- Hemorrhage: Fatal cases have occurred. Monitor for signs of bleeding and manage promptly. (5.2)
- HIT or HITT: Monitor for signs and symptoms and discontinue if indicative of HIT or HITT. (5.3)
- Thrombocytopenia: Monitor platelet count during therapy; discontinue heparin in HIT or HITT is suspected. (5.4)
- Monitoring: Blood coagulation tests guide therapy for full-dose heparin. Monitor platelet count and hematocrit in all patients receiving heparin. (5.5)
- Heparin Resistance: Increased resistance to heparin is frequently encountered in fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, myocardial infarction, cancer and in postsurgical patients. (5.6)
- Hypersensitivity Reactions: Use in patients with prior reactions only in life-threatening situations. (5.7)
- Hyperkalemia: Measure plasma potassium in patients at risk of hyperkalemia before starting heparin therapy and periodically in all patients (5.8)
- Elevations of serum aminotransferases: Interpret elevation of these enzymes with caution. (5.9)

ADVERSE REACTIONS

Most common adverse reactions are: hemorrhage, thrombocytopenia, HIT or HITT, heparin resistance, hypersensitivity reactions, hyperkalemia, and elevations of aminotransferase levels. (6)

To report SUSPECTED ADVERSE REACTIONS, contact B. Braun Medical Inc. at 1-800-227-2862 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Drugs that interfere with coagulation, platelet aggregation or drugs that counteract coagulation may induce bleeding. (7)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 7/2023

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Preparation for Administration
- 2.2 Laboratory Monitoring for Efficacy and Safety
- 2.3 Therapeutic Anticoagulant Effect with Full-Dose Heparin
- 2.4 Pediatric Use
- 2.5 Cardiovascular Surgery
- 2.6 Converting to Warfarin
- 2.7 Converting to Oral Anticoagulants other than Warfarin
- 2.8 Extracorporeal Dialysis

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Fatal Medication Errors
- 5.2 Hemorrhage
- 5.3 Heparin-Induced Thrombocytopenia (HIT) and Heparin-Induced Thrombocytopenia and Thrombosis (HITT)
- 5.4 Thrombocytopenia
- 5.5 Coagulation Testing and Monitoring
- 5.6 Heparin Resistance
- 5.7 Hypersensitivity Reactions

5.8 Hyperkalemia

5.9 Elevations of Serum Aminotransferases

6 ADVERSE REACTIONS

6.1 Postmarketing Experience

7 DRUG INTERACTIONS

7.1 Oral Anticoagulants

7.2 Platelet Inhibitors

7.3 Other Medications that May Interfere with Heparin

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Heparin Sodium in 5% Dextrose Injection is indicated for:

- Prophylaxis and treatment of venous thrombosis and pulmonary embolism
- Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation
- Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation)
- Prevention of clotting in arterial and cardiac surgery
- Prophylaxis and treatment of peripheral arterial embolism
- Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

2 DOSAGE AND ADMINISTRATION

2.1 Preparation for Administration

Confirm the selection of the correct formulation and strength prior to administration of the drug.

This product should be administered by intravenous infusion.

Do not use Heparin Sodium in 5% Dextrose Injection as a “catheter lock flush” product.

Do not admix with other drugs.

Discard unused portion.

Do not use plastic containers in series connection.

This product should not be infused under pressure.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use only if solution is clear and container and seals are intact.

2.2 Laboratory Monitoring for Efficacy and Safety

Adjust the dosage of heparin sodium according to the patient’s coagulation test results. When heparin is given by continuous intravenous infusion, determine the coagulation time approximately every 4 hours in the early stages of treatment. When the drug is administered intermittently by intravenous injection, perform coagulation tests before each injection during the early stages of treatment and at appropriate intervals thereafter. Dosage is considered adequate when the activated partial thromboplastin time (APTT) is 1.5 to 2 times the normal or when the whole blood clotting time is elevated approximately 2.5 to 3 times the control value.

Periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.

2.3 Therapeutic Anticoagulant Effect with Full-Dose Heparin

The dosing recommendations in Table 1 are based on clinical experience. Although dosage must be adjusted for the individual patient according to the results of suitable laboratory tests, the following dosage schedules may be used as guidelines:

Table 1: Recommended Adult Full-Dose Heparin Regimens for Therapeutic Anticoagulant Effect

Method of Administration	Frequency	Recommended Dose*
Intermittent Intravenous Injection	Initial Dose	10,000 Units
	Subsequent Doses	5,000 to 10,000 Units every 4 to 6 hours
Continuous Intravenous Infusion	Initial Dose	5,000 Units by intravenous injection
	Continuous	20,000 to 40,000 Units every 24 hours

* Based on 150 lb. (68 kg) patient.

2.4 Pediatric Use

There are no adequate and well-controlled studies on heparin use in pediatric patients. Pediatric dosing recommendations are based on clinical experience. In general, the

following dosage schedule may be used as a guideline in pediatric patients:

Initial Dose	75 units/kg to 100 units/kg (intravenous bolus over 10 minutes)
Maintenance Dose	Infants: 25 units/kg/hour to 30 units/kg/hour; Infants < 2 months have the highest requirements (average 28 units/kg/hour) Children > 1 year of age: 18 units/kg/hour to 20 units/kg/hour; Older children may require less heparin, similar to weight-adjusted adult dosage
Monitoring	Adjust heparin to maintain APTT of 60 to 85 seconds, assuming this reflects an anti-Factor Xa level of 0.35 to 0.70.

2.5 Cardiovascular Surgery

Patients undergoing total body perfusion for open-heart surgery should receive an initial dose of not less than 150 units of heparin sodium per kilogram of body weight. Frequently, a dose of 300 units per kilogram is used for procedures estimated to last less than 60 minutes or 400 units per kilogram for those estimated to last longer than 60 minutes.

2.6 Converting to Warfarin

To ensure continuous anticoagulation when converting from HEPARIN SODIUM to warfarin, continue full heparin therapy for several days until the INR (prothrombin time) has reached a stable therapeutic range. Heparin therapy may then be discontinued without tapering [see *Drug Interactions (7.1)*].

2.7 Converting to Oral Anticoagulants other than Warfarin

For patients currently receiving intravenous heparin, stop intravenous infusion of heparin sodium immediately after administering the first dose of oral anticoagulant; or for intermittent intravenous administration of heparin sodium, start oral anticoagulant 0 to 2 hours before the time that the next dose of heparin was to have been administered.

2.8 Extracorporeal Dialysis

Follow equipment manufacturer's operating directions carefully. A dose of 25 to 30 units/kg followed by an infusion rate of 1,500 to 2,000 units/hour is suggested based on pharmacodynamic data if specific manufacturers' recommendations are not available.

3 DOSAGE FORMS AND STRENGTHS

HEPARIN SODIUM IN 5% DEXTROSE INJECTION is available as:

- Heparin Sodium 20,000 USP units per 500 mL (40 USP units per mL) in 5% Dextrose Injection.
- Heparin Sodium 25,000 USP units per 500 mL (50 USP units per mL) in 5%

Dextrose Injection.

- Heparin Sodium 25,000 USP units per 250 mL (100 USP units per mL) in 5% Dextrose Injection.

4 CONTRAINDICATIONS

The use of HEPARIN SODIUM in 5% Dextrose Injection is contraindicated in patients with the following conditions:

- History of heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia and thrombosis (HITT) [*see Warnings and Precautions (5.3)*]
- Known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [*see Warnings and Precautions (5.7) and Adverse Reactions (6.1)*]
- In whom suitable blood coagulation tests – e.g., the whole blood clotting time, partial thromboplastin time, etc., – cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin) [*see Warnings and Precautions (5.5)*]
- Uncontrollable active bleeding state except when this is due to disseminated intravascular coagulation [*see Warnings and Precautions (5.2)*]

5 WARNINGS AND PRECAUTIONS

5.1 Fatal Medication Errors

Do not use this product as a “catheter lock flush” product. Heparin is supplied in various strengths. Fatal hemorrhages have occurred due to medication errors. Carefully examine all heparin products to confirm the correct container choice prior to administration of the drug.

5.2 Hemorrhage

Hemorrhage, including fatal events, has occurred in patients receiving HEPARIN SODIUM. Avoid using heparin in the presence of major bleeding, except when the benefits of heparin therapy outweigh the potential risks.

Hemorrhage can occur at virtually any site in patients receiving heparin. Adrenal hemorrhage (with resultant acute adrenal insufficiency), ovarian hemorrhage, and retroperitoneal hemorrhage have occurred during anticoagulant therapy with heparin [*see Adverse Reactions (6.1)*]. A higher incidence of bleeding has been reported in patients, particularly women, over 60 years of age [*see Clinical Pharmacology (12.3)*]. An unexplained fall in hematocrit or fall in blood pressure should lead to serious consideration of a hemorrhagic event.

Use heparin sodium with caution in disease states in which there is increased risk of hemorrhage, including:

- Cardiovascular – Subacute bacterial endocarditis. Severe hypertension.
- Surgical – During and immediately following (a) spinal tap or spinal anesthesia or (b) major surgery, especially involving the brain, spinal cord or eye.
- Hematologic – Conditions associated with increased bleeding tendencies, such as hemophilia, thrombocytopenia and some vascular purpuras.

- Patients with hereditary antithrombin III deficiency receiving concurrent antithrombin III therapy – The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency. To reduce the risk of bleeding, reduce the heparin dose during concomitant treatment with antithrombin III (human).
- Gastrointestinal – Ulcerative lesions and continuous tube drainage of the stomach or small intestine.
- Other – Menstruation, liver disease with impaired hemostasis.

5.3 Heparin-Induced Thrombocytopenia (HIT) and Heparin-Induced Thrombocytopenia and Thrombosis (HITT)

HIT is a serious immune-mediated reaction resulting from irreversible aggregation of platelets. HIT occurs in patients treated with heparin and is due to the development of antibodies to a platelet Factor 4-heparin complex that induce *in vivo* platelet aggregation. HIT may progress to the development of venous and arterial thromboses, a condition known as HITT. Thrombotic events may also be the initial presentation for HIT. These serious thromboembolic events include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, thrombus formation on a prosthetic cardiac valve, mesenteric thrombosis, renal arterial thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.

Once HIT or HITT is diagnosed or strongly suspected, discontinue all heparin sources (including heparin flushes) and use an alternative anticoagulant.

Immune-mediated HIT is diagnosed based on clinical findings supplemented by laboratory tests confirming the presence of antibodies to heparin, or platelet activation induced by heparin. Obtain platelet counts at baseline and periodically during heparin administration. A drop in platelet count greater than 50% from baseline is considered indicative of HIT. Platelet counts begin to fall 5 to 10 days after exposure to heparin in heparin-naïve individuals and reach a threshold by days 7 to 14. In contrast, “rapid onset” HIT can occur very quickly (within 24 hours following heparin initiation), especially in patients with a recent exposure to heparin (i.e., previous 3 months).

Thrombosis development shortly after documenting thrombocytopenia is a characteristic finding in almost half of all patients with HIT.

Monitor thrombocytopenia of any degree closely. If the platelet count falls below 100,000/mm³ or if recurrent thrombosis develops, promptly discontinue heparin, evaluate for HIT and HITT, and, if necessary, administer an alternative anticoagulant.

HIT or HITT can occur up to several weeks after the discontinuation of heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT or HITT.

5.4 Thrombocytopenia

Thrombocytopenia has been reported to occur in patients receiving heparin with a reported incidence of up to 30%. It can occur 2 to 20 days (average 5 to 9) following the onset of heparin therapy. Obtain platelet counts before and periodically during heparin therapy. Monitor thrombocytopenia of any degree closely. If the count falls below 100,000/mm³ or if recurrent thrombosis develops, promptly discontinue heparin,

evaluate for HIT, and, if necessary, administer an alternative anticoagulant [see *Warnings and Precautions (5.3)*].

5.5 Coagulation Testing and Monitoring

When using a full dose heparin regimen, adjust the heparin dose based on frequent blood coagulation tests. If the coagulation test is unduly prolonged or if hemorrhage occurs, heparin sodium should be discontinued promptly [see *Overdosage (10)*]. Periodic platelet counts, hematocrits are recommended during the entire course of heparin therapy [see *Dosage and Administration (2.2)*].

5.6 Heparin Resistance

Increased resistance to heparin is frequently encountered in fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, myocardial infarction, cancer and in postsurgical patients, and patients with antithrombin III deficiency.

Consider measurement of anti-thrombin levels if heparin resistance is suspected. Monitor coagulation tests frequently in such patients. It may be necessary to adjust the dose of heparin based on coagulation test monitoring, such as anti-Factor Xa levels and/or partial thromboplastin time.

5.7 Hypersensitivity Reactions

Hypersensitivity reactions with chills, fever and urticaria as the most usual manifestations and also asthma, rhinitis, lacrimation, and anaphylactoid reactions have been reported. Patients with documented hypersensitivity to heparin should be given the drug only in clearly life-threatening situations [see *Adverse Reactions (6.1)*].

Because Heparin Sodium in 5% Dextrose Injection is derived from animal tissue, monitor for signs and symptoms of hypersensitivity when it is used in patients with a history of allergy to pork products.

This product contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

5.8 Hyperkalemia

Heparin can suppress adrenal secretion of aldosterone leading to hyperkalemia, particularly in patients with diabetes mellitus, chronic renal failure, pre-existing metabolic acidosis, a raised plasma potassium, or taking potassium sparing drugs. The risk of hyperkalemia appears to increase with duration of therapy but is usually reversible upon discontinuation of heparin.

Measure plasma potassium in patients at risk of hyperkalemia before starting heparin therapy and periodically in all patients treated for more than 5 days or earlier as deemed fit by the clinician.

5.9 Elevations of Serum Aminotransferases

Significant elevations of aspartate aminotransferase (AST) and alanine aminotransferase

(ALT) levels have occurred in patients who have received heparin. Elevation of these enzymes in patients receiving heparin should be interpreted with caution. These elevations typically resolve upon heparin discontinuation.

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

- Hemorrhage [see *Warnings and Precautions (5.2)*]
- Heparin-Induced Thrombocytopenia and Heparin-Induced Thrombocytopenia with Thrombosis [see *Warnings and Precautions (5.3)*]
- Thrombocytopenia [see *Warnings and Precautions (5.4)*]
- Heparin Resistance [see *Warnings and Precautions (5.6)*]
- Hypersensitivity [see *Warnings and Precautions (5.7)*]
- Hyperkalemia [see *Warnings and Precautions (5.8)*]
- Elevations of Serum Aminotransferases [see *Warnings and Precautions (5.9)*]

6.1 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of heparin sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.

- **Hemorrhage** - Hemorrhage is the chief complication that may result from heparin therapy [see *Warnings and Precautions (5.2)*]. An overly prolonged clotting time or minor bleeding during therapy can usually be controlled by withdrawing the drug [see *Overdosage (10)*]. Gastrointestinal or urinary tract bleeding during anticoagulant therapy may indicate the presence of an underlying occult lesion. Bleeding can occur at any site but certain specific hemorrhagic complications may be difficult to detect:
 - Adrenal hemorrhage, with resultant acute adrenal insufficiency, has occurred with heparin therapy, including fatal cases.
 - Ovarian (corpus luteum) hemorrhage developed in a number of women of reproductive age receiving short- or long-term anticoagulant therapy.
 - Retroperitoneal hemorrhage.
- **Vascular Disorders** - Contusion, Vasospastic reactions (including episodes of painful, ischemic, and cyanosed limbs).
- **HIT and HITT, including delayed onset cases, and Thrombocytopenia** - [see *Warnings and Precautions (5.3 and 5.4)*]
- **Histamine-like reactions** - Such reactions have been observed at the site of injections. Necrosis of the skin has been reported at the site of subcutaneous injection of heparin, occasionally requiring skin grafting.
- **Hypersensitivity** - Generalized hypersensitivity reactions have been reported with chills, fever, and urticaria as the most usual manifestations, and asthma, rhinitis, lacrimation, headache, nausea and vomiting, and anaphylactoid reactions, including shock, occurring more rarely. Itching and burning, especially on the plantar site of the feet, may occur [see *Warnings and Precautions (5.7)*].
- **Musculoskeletal, Connective Tissue and Bone Disorders** - Osteoporosis with long-term administration of heparin.
- **Metabolism and Nutrition Disorders** - Hyperkalemia.
- **General Disorders and Administration Site Conditions** - Erythema, mild pain,

ulceration.

- **Elevations of serum aminotransferases** - Significant elevations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels have occurred in patients who have received heparin.
- **Others** - Osteoporosis following long-term administration of high-doses of heparin, cutaneous necrosis after systemic administration, suppression of aldosterone synthesis, delayed transient alopecia, priapism, and rebound hyperlipemia on discontinuation of heparin sodium have also been reported.

7 DRUG INTERACTIONS

7.1 Oral Anticoagulants

Heparin sodium may prolong the one-stage prothrombin time. Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.

7.2 Platelet Inhibitors

Drugs such as NSAIDs (including acetylsalicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. To reduce the risk of bleeding, a reduction in the dose of antiplatelet agent or heparin is recommended.

7.3 Other Medications that May Interfere with Heparin

Digitalis, tetracyclines, nicotine, antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. Intravenous nitroglycerin administered to heparinized patients may result in a decrease of the partial thromboplastin time with subsequent rebound effect upon discontinuation of nitroglycerin. Careful monitoring of partial thromboplastin time and adjustment of heparin dosage are recommended during coadministration of heparin and intravenous nitroglycerin. Antithrombin III (human) - The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency. To reduce the risk of bleeding, a reduced dosage of heparin is recommended during treatment with antithrombin III (human).

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

In published reports, heparin exposure during pregnancy did not show evidence of an increased risk of adverse maternal or fetal outcomes in humans. No teratogenicity was observed in animal reproduction studies with administration of heparin sodium to

pregnant rats and rabbits during organogenesis at doses up to 10,000 USP units/kg/day, approximately 10 times the maximum recommended human dose (MRHD) of 40,000 USP units/24 hours infusion [see *Data*]. In pregnant animals, doses up to 10 times higher than the maximum human daily dose based on body weight resulted in increased resorptions. Consider the benefits and risks of HEPARIN SODIUM IN 5% DEXTROSE INJECTION to a pregnant woman and possible risks to the fetus when prescribing HEPARIN SODIUM IN 5% DEXTROSE INJECTION.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Human Data

The maternal and fetal outcomes associated with uses of heparin via various dosing methods and administration routes during pregnancy have been investigated in numerous studies. These studies generally reported normal deliveries with no maternal or fetal bleeding and no other complications.

Animal Data

In a published study conducted in rats and rabbits, pregnant animals received heparin intravenously during organogenesis at a dose of 10,000 USP units/kg/day, approximately 10 times the maximum human daily dose based on body weight. The number of early resorptions increased in both species. There was no evidence of teratogenic effects.

8.2 Lactation

Risk Summary

There is no information regarding the presence of HEPARIN SODIUM IN 5% DEXTROSE INJECTION in human milk, the effects on the breastfed infant, or the effects on milk production. Due to its large molecular weight, heparin is not likely to be excreted in human milk, and any heparin in milk would not be orally absorbed by a nursing infant. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for HEPARIN SODIUM IN 5% DEXTROSE INJECTION and any potential adverse effects on the breastfed infant from HEPARIN SODIUM IN 5% DEXTROSE INJECTION or from the underlying maternal condition [see *Use in Specific Populations (8.4)*].

8.4 Pediatric Use

There are no adequate and well controlled studies on heparin use in pediatric patients. Pediatric dosing recommendations are based on clinical experience [see *Dosage and Administration (2.4)*].

8.5 Geriatric Use

There are limited adequate and well-controlled studies in patients 65 years and older.

However, a higher incidence of bleeding has been reported in patients over 60 years of age, especially women [see *Warnings and Precautions (5.2)*]. Lower doses of heparin may be indicated in these patients [see *Clinical Pharmacology (12.3)*].

10 OVERDOSAGE

An overdose requires immediate medical attention and treatment.

Symptoms

Bleeding is the chief sign of heparin overdose. Easy bruising, petechial formations, nosebleeds, blood in urine or tarry stools may be the first signs or symptoms of a heparin overdose. In the event of symptomatic heparin overdose, consider stopping heparin infusion.

Treatment

Neutralization of heparin effect:

When clinical circumstances (bleeding) require reversal of heparinization, protamine sulfate (1% solution) by slow infusion will neutralize heparin sodium. **No more than 50 mg** should be administered, **very slowly**, in any 10 minute period. Each mg of protamine sulfate neutralizes approximately 100 USP Heparin units. The amount of protamine required decreases over time as heparin is metabolized. Although the metabolism of heparin is complex, it may, for the purpose of choosing a protamine dose, be assumed to have a half-life of about 30 minutes after intravenous injection.

Ideally, the dose required to neutralize the action of heparin should be guided by blood coagulation tests or calculated from a protamine neutralization test.

Because fatal reactions often resembling anaphylaxis have been reported, protamine sulfate should be given only when resuscitation techniques and treatment of anaphylactoid shock are readily available.


For additional information, consult the prescribing information for Protamine Sulfate Injection, USP.

Blood or plasma transfusions may be necessary; these dilute but do not neutralize heparin.

11 DESCRIPTION

Heparin is a heterogenous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycans having anticoagulant properties. It is composed of polymers of alternating derivations of alpha-L-iduronic acid 2-sulfate (1), 2-deoxy-2-sulfamino- alpha-D-glucose 6-sulfate (2), beta-D-glucuronic acid (3), 2-acetamido-2- deoxy-alpha-D-glucose (4), and alpha-L-iduronic acid (5).

Structure of Heparin Sodium (representative subunits):



Heparin Sodium in 5% Dextrose Injection is a sterile, nonpyrogenic solution prepared from Heparin Sodium USP (derived from porcine intestinal mucosa and standardized for use as an anticoagulant) and Hydrous Dextrose USP. It is to be administered by intravenous injection. The potency is determined by a biological assay using a USP reference standard based on units of heparin activity per milligram.

The pH range is 5.6 (4.5 – 7.0) and the osmolarity mOsmol/L (calc.) is 315. The concentration of electrolytes is 38 mEq/L Sodium, 30 mEq/L Phosphate, and 15 mEq/L Citrate.

40 USP units/mL: Each 100 mL of the 20,000 USP units per 500 mL preparation contains: 4,000 USP units of heparin sodium, 5 g Hydrous Dextrose USP, 0.41 g Dibasic Sodium Phosphate, 0.093 g Citric Acid Anhydrous USP, 0.0686 g Sodium Metabisulfite NF (antioxidant), and Water for Injection USP until quantity sufficient.

50 USP units/mL: Each 100 mL of the 25,000 USP units per 500 mL preparation contains: 5,000 USP units of heparin sodium, 5 g Hydrous Dextrose USP, 0.41 g Dibasic Sodium Phosphate, 0.093 g Citric Acid Anhydrous USP, 0.0686 g Sodium Metabisulfite NF (antioxidant), and Water for Injection USP until quantity sufficient.

100 USP units/mL: Each 100 mL of the 25,000 USP units per 250 mL preparation contains: 10,000 USP units of heparin sodium, 5 g Hydrous Dextrose USP, 0.41 g Dibasic Sodium Phosphate, 0.093 g Citric Acid Anhydrous USP, 0.0686 g Sodium Metabisulfite NF (antioxidant), and Water for Injection USP until quantity sufficient.

The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.

The plastic container is not made with natural rubber latex, PVC or DEHP.

The closure system has two ports; the one for the administration set has a tamper evident plastic protector.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Heparin interacts with the naturally occurring plasma protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and larger amounts inhibit thrombin (Factor IIa). Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin does not have fibrinolytic activity; therefore, it will not lyse existing clots.

12.2 Pharmacodynamics

Various times (activated clotting time, activated partial thromboplastin time, prothrombin time, whole blood clotting time) are prolonged by full therapeutic doses of heparin; in most cases, they are not measurably affected by low doses of heparin. Bleeding time is usually unaffected by heparin.

12.3 Pharmacokinetics

Absorption

Heparin is not absorbed through the gastrointestinal tract and therefore administered via parenteral route. Peak plasma concentration and the onset of action are achieved immediately after intravenous administration.

Distribution

Heparin is highly bound to antithrombin, fibrinogens, globulins, serum proteases and lipoproteins. The volume of distribution is 0.07 L/kg.

Elimination

Metabolism

Heparin does not undergo enzymatic degradation.

Excretion

Heparin is mainly cleared from the circulation by liver and reticuloendothelial cells mediated uptake into extravascular space. Heparin undergoes biphasic clearance, a) rapid saturable clearance (zero order process due to binding to proteins, endothelial cells and macrophages) and b) slower first order elimination. Low doses of heparin are cleared mostly by a saturable, rapid, zero-order process. Slower first order elimination usually occurs with very high doses of heparin and is dependent on renal function. The plasma half-life is dose-dependent, and it ranges from 0.5 to 2 h.

Specific Populations

Geriatric Patients

Patients over 60 years of age, following similar doses of heparin, may have higher plasma levels of heparin and longer activated partial thromboplastin times (APTTs) compared with patients under 60 years of age [see *Use in Specific Populations (8.5)*].

Renal and Hepatic Impairment

The rate of clearance of unfractionated heparin may be decreased in patients with renal

or hepatic impairment. Patients with renal or hepatic impairment, following similar doses of heparin may have higher plasma levels of heparin compared with patient with normal renal and hepatic function [see *Warnings and Precautions (5.2)*].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term studies in animals to evaluate the carcinogenic potential, reproduction studies in animals to determine effects on fertility of males and females, and the studies to determine mutagenic potential have not been conducted.

16 HOW SUPPLIED/STORAGE AND HANDLING

Heparin Sodium in 5% Dextrose Injection is supplied sterile and nonpyrogenic in single-dose EXCEL® Containers packaged 24 per case.

<u>NDC</u>	<u>REF</u>	<u>Concentration</u>	<u>Size</u>
0264-9567-10	P5671	Heparin Sodium 20,000 USP units per 500 mL (40 USP units per mL) in 5% Dextrose Injection	500 mL
0264-9577-10	P5771	Heparin Sodium 25,000 USP units per 500 mL (50 USP units per mL) in 5% Dextrose Injection	500 mL
0264-9587-20	P5872	Heparin Sodium 25,000 USP units per 250 mL (100 USP units per mL) in 5% Dextrose Injection	250 mL

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing.

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.]

17 PATIENT COUNSELING INFORMATION

Hemorrhage

Inform patients that it may take them longer than usual to stop bleeding, that they may bruise and/or bleed more easily when they are treated with heparin, and that they should report any unusual bleeding or bruising to their physician. Hemorrhage can occur at virtually any site in patients receiving heparin. Fatal hemorrhages have occurred [see *Warnings and Precautions (5.2)*].

Prior to Surgery

Advise patients to inform physicians and dentists that they are receiving heparin before any surgery is scheduled [see *Warnings and Precautions (5.2)*].

Heparin-Induced Thrombocytopenia

Inform patients of the risk of heparin-induced thrombocytopenia (HIT). HIT may progress to the development of venous and arterial thromboses, a condition known as heparin-induced thrombocytopenia and thrombosis (HITT). HIT or HITT can occur up to several weeks after the discontinuation of heparin therapy [see *Warnings and Precautions (5.3 and 5.4)*].

Hypersensitivity

Inform patients that generalized hypersensitivity reactions have been reported. Necrosis of the skin has been reported at the site of subcutaneous injection of heparin [see *Warnings and Precautions (5.7)*, *Adverse Reactions (6)*].

Other Medications

Because of the risk of hemorrhage, advise patients to inform their physicians and dentists of all medications they are taking, including non-prescription medications, and before starting any new medication [see *Drug Interactions (7.2)*].

Rx only

EXCEL is a registered trademark of B. Braun Medical Inc.

B. Braun Medical Inc.

Bethlehem, PA 18018-3524 USA
1-800-227-2862

Y36-003-071 LD-239-9

PRINCIPAL DISPLAY PANEL - 500 mL container

NDC 0264-9567-10

HEPARIN SODIUM in

5% Dextrose Injection

20,000 USP units per 500 mL

(40 USP units per mL)

LD-306-5 Y94-003-488

For Intravenous Use Only

Each 100 mL contains: Heparin Sodium USP (porcine intestinal mucosa)

4,000 USP Heparin units; Hydrous Dextrose USP 5 g;

Dibasic Sodium Phosphate•7H₂O USP 0.41 g; Citric Acid Anhydrous USP 0.093 g;

Sodium Metabisulfite NF (antioxidant) <0.07 g; Water for Injection USP qs

Electrolytes (mEq/liter): Sodium 38; Phosphate (HPO⁻²) 30; Citrate 15

WARNING: CONTAINS SULFITES. Do not admix with other drugs.

Sterile. Single dose container. Discard unused portion.

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat. Protect from freezing. Recommended Dosage: see Prescribing Information. Do not remove overwrap until ready for use.

Not made with natural rubber latex, PVC or DEHP.

EXCEL is a registered trademark of B. Braun Medical Inc.

500 mL EXCEL[®] CONTAINER

Rx only

REF P5671

B. Braun Medical Inc.

Bethlehem, PA 18018-3524 USA

1-800-227-2862

Prepared in USA. API from Spain.

Y94-003-487 LD-305-5

EXP

LOT

ARTWORK FREE AREA

NDC 0264-9567-10

LD-306-5
Y94-003-486

HEPARIN SODIUM in 5% Dextrose Injection

20,000 USP units per 500 mL (40 USP units per mL)

For Intravenous Use Only

Each 100 mL contains: Heparin Sodium USP (porcine intestinal mucosa) 4,000 USP Heparin units; Hydrous Dextrose USP 5 g; Dibasic Sodium Phosphate•7H₂O USP 0.41 g; Citric Acid Anhydrous USP 0.093 g; Sodium Metabisulfite NF (antioxidant) <0.07 g; Water for Injection USP qs
Electrolytes (mEq/liter): Sodium 38; Phosphate (HPO₄⁻) 30; Citrate 15

WARNING: CONTAINS SULFITES. Do not admix with other drugs.

Sterile. Single dose container. Discard unused portion.

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat. Protect from freezing. Recommended Dosage: see Prescribing Information. Do not remove overwrap until ready for use.

Not made with natural rubber latex, PVC or DEHP.

500 mL
EXCEL® CONTAINER

Rx only REF P5671

ARTWORK FREE BARCODE AREA

2D
CODE

BARCODE

BARCODE

Y94-003-487 LD-306-5



EXCEL is a registered trademark of B. Braun Medical Inc.

B | BRAUN

B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862
Prepared in USA. API from Spain.

EXP MM/YY X LOT XXXXXX

-0-
-1-
-2-
-3-
-4-

PRINCIPAL DISPLAY PANEL - 500 mL container

NDC 0264-9577-10

HEPARIN SODIUM in

5% Dextrose Injection

25,000 USP units per 500 mL

(50 USP units per mL)

LD-308-7 Y94-003-490

For Intravenous Use Only

Each 100 mL contains: Heparin Sodium USP (porcine intestinal mucosa) 5,000 USP Heparin units; Hydrous Dextrose USP 5 g; Dibasic Sodium Phosphate•7H₂O USP 0.41 g; Citric Acid Anhydrous USP 0.093 g; Sodium Metabisulfite NF (antioxidant) <0.07 g; Water for Injection USP qs

Electrolytes (mEq/liter): Sodium 38; Phosphate (HPO₄⁼) 30; Citrate 15

WARNING: CONTAINS SULFITES. Do not admix with other drugs.

Sterile. Single dose container. Discard unused portion.

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat. Protect from freezing. Recommended Dosage: see Prescribing Information. Do not remove overwrap until ready for use.

Not made with natural rubber latex, PVC or DEHP.

EXCEL is a registered trademark of B. Braun Medical Inc.

500 mL EXCEL[®] CONTAINER

Rx only

REF P5771

B. Braun Medical Inc.

Bethlehem, PA 18018-3524 USA

1-800-227-2862

Prepared in USA. API from Spain.

Y94-003-489 LD-307-6

EXP

LOT

ARTWORK FREE AREA

NDC 0264-9577-10

LD-307-7
Y94-003-490

HEPARIN SODIUM in

5% Dextrose Injection

25,000 USP units per 500 mL
(50 USP units per mL)

For Intravenous Use Only

Each 100 mL contains: Heparin Sodium USP (porcine intestinal mucosa) 5,000 USP Heparin units; Hydrous Dextrose USP 5 g; Dibasic Sodium Phosphate•7H₂O USP 0.41 g; Citric Acid Anhydrous USP 0.093 g; Sodium Metabisulfite NF (antioxidant) <0.07 g; Water for Injection USP qs
Electrolytes (mEq/liter): Sodium 38; Phosphate (HPO₄⁻) 30; Citrate 15

WARNING: CONTAINS SULFITES. Do not admix with other drugs.

Sterile. Single dose container. Discard unused portion.

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat. Protect from freezing. Recommended Dosage: see Prescribing Information. Do not remove overwrap until ready for use.

Not made with natural rubber latex, PVC or DEHP.

500 mL
EXCEL[®] CONTAINER Rx only REF P5771

ARTWORK FREE BARCODE AREA

2D
CODE

BARCODE

BARCODE

Y94-003-489 LD-307-6



EXCEL is a registered trademark of B. Braun Medical Inc.

B | BRAUN

B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862
Prepared in USA. API from Spain.

EXP MM/YY X LOT XXXXXX

-0-
-1-
-2-
-3-
-4-

PRINCIPAL DISPLAY PANEL - 250 mL container

NDC 0264-9587-20

HEPARIN SODIUM in

5% Dextrose Injection

25,000 USP units per 250 mL

(100 USP units per mL)

LD-310-8 Y94-003-492

For Intravenous Use Only

Each 100 mL contains: Heparin Sodium USP (porcine intestinal mucosa) 10,000 USP Heparin units; Hydrous Dextrose USP 5 g; Dibasic Sodium Phosphate•7H₂O USP 0.41 g; Citric Acid Anhydrous USP 0.093 g; Sodium Metabisulfite NF (antioxidant) <0.07 g; Water for Injection USP qs

Electrolytes (mEq/liter): Sodium 38; Phosphate (HPO₄²⁻) 30; Citrate 15

WARNING: CONTAINS SULFITES. Do not admix with other drugs.

Sterile. Single dose container. Discard unused portion.

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat. Protect from freezing. Recommended Dosage: see Prescribing Information. Do not remove overwrap until ready for use.

Not made with natural rubber latex, PVC or DEHP.

EXCEL is a registered trademark of B. Braun Medical Inc.

250 mL EXCEL[®] CONTAINER

Rx only

REF P5872

B. Braun Medical Inc.

Bethlehem, PA 18018-3524 USA
1-800-227-2862

Prepared in USA. API from Spain.

Y94-003-491 LD-309-7

EXP
LOT

ARTWORK FREE AREA

NDC 0264-9587-20

110 310 8
Y94-003-482

HEPARIN SODIUM in 5% Dextrose Injection

25,000 USP units per 250 mL
(100 USP units per mL)

For Intravenous Use Only

Each 100 mL contains: Heparin Sodium USP (porcine intestinal mucosa) 10,000 USP Heparin units; Hydrous Dextrose USP 5 g; Dibasic Sodium Phosphate•7H₂O USP 0.41 g; Citric Acid Anhydrous USP 0.093 g; Sodium Metabisulfite NF (antioxidant) <0.07 g; Water for Injection USP qs
Electrolytes (mEq/liter): Sodium 38; Phosphate (HPO₄²⁻) 30; Citrate 15

50

WARNING: CONTAINS SULFITES. Do not admix with other drugs. Sterile. Single dose container. Discard unused portion.

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat. Protect from freezing. Recommended Dosage: see Prescribing Information. Do not remove overwrap until ready for use. Not made with natural rubber latex, PVC or DEHP. Rx only

100

EXCEL is a registered trademark of B. Braun Medical Inc.

250 mL
EXCEL® CONTAINER

REF P5872

150

ARTWORK FREE BARCODE AREA

2D
CODE

BARCODE

BARCODE

Y94-003-481 LD-308-7

200



B BRAUN

B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862
Prepared in USA. API from Spain.

EXP MM/YY X LOT XXXXXX

HEPARIN SODIUM IN DEXTROSE

heparin sodium and dextrose injection

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0264-9567	
Route of Administration	INTRAVENOUS			
Active Ingredient/Active Moiety				
Ingredient Name		Basis of Strength	Strength	
HEPARIN SODIUM (UNII: ZZ45AB24CA) (HEPARIN - UNII:T2410KM04A)		HEPARIN	4000 [USP'U] in 100 mL	
DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SLOG7R0OK)		DEXTROSE MONOHYDRATE	5 g in 100 mL	
Inactive Ingredients				
Ingredient Name			Strength	
WATER (UNII: 059QF0KO0R)				
SODIUM PHOSPHATE, DIBASIC (UNII: GR686LBA74)			0.41 g in 100 mL	
ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)			0.093 g in 100 mL	
SODIUM METABISULFITE (UNII: 4VON5FNS3C)			0.07 g in 100 mL	
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0264-9567-10	24 in 1 CASE	07/20/1992	
1		500 mL in 1 CONTAINER; Type 0: Not a Combination Product		
Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
NDA	NDA019952	07/20/1992		

HEPARIN SODIUM IN DEXTROSE

heparin sodium and dextrose injection

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0264-9577	
Route of Administration	INTRAVENOUS			
Active Ingredient/Active Moiety				
Ingredient Name		Basis of Strength	Strength	
HEPARIN SODIUM (UNII: ZZ45AB24CA) (HEPARIN - UNII:T2410KM04A)		HEPARIN	4000 [USP'U] in 100 mL	
DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SLOG7R0OK)		DEXTROSE MONOHYDRATE	5 g in 100 mL	

HEPARIN SODIUM (UNII: ZZ45AB24CA) (HEPARIN - UNII:T2410KM04A)		HEPARIN	5000 [USP U] in 100 mL	
DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SLOG7R0OK)		DEXTROSE MONOHYDRATE	5 g in 100 mL	
Inactive Ingredients				
Ingredient Name		Strength		
WATER (UNII: 059QF0KO0R)				
SODIUM PHOSPHATE, DIBASIC (UNII: GR686LBA74)		0.41 g in 100 mL		
ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)		0.093 g in 100 mL		
SODIUM METABISULFITE (UNII: 4VON5FNS3C)		0.07 g in 100 mL		
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0264-9577-10	24 in 1 CASE	07/20/1992	
1		500 mL in 1 CONTAINER; Type 0: Not a Combination Product		
Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
NDA	NDA019952	07/20/1992		

HEPARIN SODIUM IN DEXTROSE

heparin sodium and dextrose injection

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0264-9587
Route of Administration	INTRAVENOUS		
Active Ingredient/Active Moiety			
Ingredient Name		Basis of Strength	Strength
HEPARIN SODIUM (UNII: ZZ45AB24CA) (HEPARIN - UNII:T2410KM04A)		HEPARIN	10000 [USP'U] in 100 mL
DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SLOG7R0OK)		DEXTROSE MONOHYDRATE	5 g in 100 mL
Inactive Ingredients			
Ingredient Name		Strength	
WATER (UNII: 059QF0KO0R)			

SODIUM PHOSPHATE, DIBASIC (UNII: GR686LBA74)	0.41 g in 100 mL
ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)	0.093 g in 100 mL
SODIUM METABISULFITE (UNII: 4VON5FNS3C)	0.07 g in 100 mL

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0264-9587-20	24 in 1 CASE	07/20/1992	
1		250 mL in 1 CONTAINER; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA019952	07/20/1992	

Labeler - B. Braun Medical Inc. (002397347)

Revised: 7/2023

B. Braun Medical Inc.